Zacks Investment ResearchFri, 29 May 2026 18:31:07 GMTIBRX and the BCG Shortage: Deals That Could Expand DemandIBRX+11.81%
Zacks Investment ResearchFri, 29 May 2026 18:25:40 GMTImmunityBio: Anktiva Explained and What Comes NextIBRX+11.81%
Zacks Investment ResearchFri, 29 May 2026 18:25:33 GMTIBRX Stock Outlook After Q1 Results and a New FDA ReviewIBRX+11.81%
Seeking AlphaWed, 20 May 2026 16:07:31 GMTImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar BreakoutIBRX+11.81%
Zacks Investment ResearchWed, 20 May 2026 14:55:23 GMTFDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer TherapyIBRX+11.81%
BenzingaWed, 20 May 2026 12:49:56 GMTImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer DrugIBRX+11.81%
BenzingaTue, 19 May 2026 16:57:10 GMTImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer TherapiesIBRX+11.81%
Zacks Investment ResearchTue, 19 May 2026 15:46:12 GMTImmunityBio Secures Five U.S. Patents for Anktiva in Bladder CancerIBRX+11.81%
Seeking AlphaTue, 19 May 2026 14:04:30 GMTImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAMIBRX+11.81%
BenzingaThu, 07 May 2026 17:53:28 GMTImmunityBio Stock Drops After Earnings Miss Despite Anktiva MomentumIBRX+11.81%
Zacks Investment ResearchThu, 07 May 2026 13:55:49 GMTImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue EstimatesIBRX+11.81%
Zacks Investment ResearchMon, 04 May 2026 18:10:16 GMTImmunityBio to Report Q1 Earnings: What's in the Cards?IBRX+11.81%
Zacks Investment ResearchMon, 27 Apr 2026 17:36:18 GMTIBRX Global Rollout: EU, MENA, and Asia Shape 2026-27 CatalystsIBRX+11.81%
Zacks Investment ResearchMon, 27 Apr 2026 17:30:37 GMTIBRX: What Anktiva's Bladder Data Says About 2026 SalesIBRX+11.81%
Zacks Investment ResearchMon, 27 Apr 2026 17:30:30 GMTIs IBRX Priced for Perfection at Nearly 28x Forward Sales?IBRX+11.81%
Zacks Investment ResearchMon, 27 Apr 2026 17:02:22 GMTWhat Makes ImmunityBio (IBRX) a New Buy StockIBRX+11.81%
BenzingaTue, 21 Apr 2026 13:44:07 GMTImmunityBio Stock Rises As ANKTIVA Launches in Saudi ArabiaIBRX+11.81%
Seeking AlphaFri, 17 Apr 2026 11:49:30 GMTReframing ImmunityBio: The Long-Term Platform Opportunity Beyond AnktivaIBRX+11.81%
Zacks Investment ResearchFri, 10 Apr 2026 19:55:25 GMTIBRX Stock Rises 7% on Strong Q1 2026 Preliminary ResultsIBRX+11.81%